Is the business good?
How good a business is GLUE?
Monte Rosa Therapeutics, Inc. keeps −633% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−633%
Operating margin · Biotechnology median −72% · 12 months to Q2 2026
- Share count, year on year
- +23%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 594%
R&D as % of revenue
Details›
- Operating margin12 months to Q2 2026
- −633%
- Net margin12 months to Q2 2026
- −561%
- Free cash flow margin
- −112%
- R&D as % of revenue
- 594%
- Revenue, trailing twelve months
- $29M
- Free cash flow, trailing twelve months
- −$32M
- Net income, trailing twelve months
- −$161M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.